N4 Pharma in very good shape as it moves forward (Interview)

N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss the latest interim results. Nigel talks us through the highlights of the first half, expands on a new refined strategy to focus on three clearly defined work streams, how the Covid pandemic has presented opportunities for the business and what investors can expect from N4 Pharma for the remainder of the year.

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

The business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    DirectorsTalk

    More articles like this

    N4 Pharma

    N4 Pharma Q&A: A pivotal time for the company (LON:N4P)

    N4 Pharma’s Nigel Theobald discusses final results, updates on the three work streams, the European patent for Nuvec & what this means for the company and what investors can expect in the near future in this exclusive interview with DirectorsTalk.

    N4 Pharma

    N4 Pharma AGM to be held at 10.00am on 24 March 2021

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2020, together with the notice of

    DirectorsTalk

    With the focus on drug delivery can N4 Pharma fill a need in the market?

    N4 Pharma plc (LON:N4P) are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs

    DirectorsTalk

    N4 Pharma raises £2 million through placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary shares of

    DirectorsTalk

    N4 Pharma update on Nanomerics research collaboration

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February